Innovate Biopharmaceuticals

Innovate Biopharmaceuticals is a publicly traded, clinical-stage biotechnology company dedicated to developing new drugs for autoimmune and inflammatory diseases with unmet needs. Its lead compound, INN-202, targets celiac disease, an inflammatory bowel condition that affects 3 million people in the United States and approximately 15 million people worldwide.